Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma
Multiple myeloma (MM), one of the most common hematological neoplasms worldwide, originates from malignant plasma cells in the bone marrow. MM remains an incurable disease, although continued treatment advancements have markedly increased overall survival. Many patients with MM eventually experience
Authors
- Yuqing Weng (ORCID: https://orcid.org/0000-0002-8558-0336)
- Xiaoyan Han
- Heng Mei (ORCID: https://orcid.org/0000-0001-7941-2443)
- Zhuoxiao Cao
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- Gaofeng Zheng
- Cheng Wen
- Donghua He (ORCID: https://orcid.org/0000-0002-9268-8732)
- Ruyi Xu
Institutions
- Union Hospital (HK)
- Shanghai CASB Biotechnology (China) (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-10-17
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2024.0581
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China